MONOTHERAPY WITH CALCIPOTRIOL OR BETAMETHASONE have both been useful in the treatment of psoriasis. This study evaluates the efficacy of a new combination ointment containing both calcipotriol and betamethasone dipropionate compared with betamethasone dipropionate ointment (Diprosone) and calcipotriol ointment (Daivonex) alone in patients with psoriasis vulgaris. A total of 1106 patients were randomized to twice daily double-blind treatment with combination, betamethasone dipropionate, or calcipotriol for 4 weeks. Patients then received twice daily calcipotriol, unblinded, for a further 4 weeks. Mean percentage in PASI at end of the double-blind phase was -74.4 (combination group), -61.3 (betamethasone group), and -55.3 (calcipotriol group). Mean difference (95% Cl) combination-betamethasone was -13.1 (-16.9 to -9.3, p <0.001) and for combination-calcipotriol -19.0 (-22.8 to -15.2, p <0.001). The differences in PASI were also statistically significant after 1 week. This study showed that calcipotriol/betamethasone combination is more effective and has a more rapid onset of action than either active constituent used alone, and is well tolerated.
Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82(2):131-5.
COPYRIGHT 2003 Journal of Drugs in Dermatology
COPYRIGHT 2003 Gale Group
Contact
Home
A
Baciim